MIR23C: A Potential Drug Target and Biomarker (G100500809)
MIR23C: A Potential Drug Target and Biomarker
Mir23C, a protein encoded by the MIR23 gene, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of these diseases.
MIR23C: Structure and Function
MIR23C is a 23-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. It is composed of a unique arrangement of 11 transmembrane domains, two intracellular domains, and one extracellular domain. The transmembrane domains are responsible for the protein's unique structure and function, as they are involved in the regulation of various cellular processes, including signaling pathways and ion channels.
One of the most significant features of MIR23C is its unique farnesylated cysteine residue, which is located in the N-terminus of the protein. This cysteine residue is known for its ability to undergo a series of chemical modifications, including acetylation and lysine modification, which have been shown to play important roles in various cellular processes.
MIR23C's intracellular domain is composed of a unique arrangement of 11尾-helices, which are involved in the regulation of various cellular processes, including cell signaling pathways and protein-protein interactions. The extracellular domain of MIR23C is composed of a unique arrangement of 11 transmembrane domains, which are involved in the regulation of various cellular processes, including the regulation of ion channels and signaling pathways.
MIR23C's unique structure and function have made it an attractive target for researchers to investigate. The potential drug target that MIR23C may serve is the regulation of cellular signaling pathways, including the regulation of cell proliferation, apoptosis, and neurodegenerative diseases.
MIR23C as a Biomarker
MIR23C has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique structure and function of MIR23C have made it an attractive target for the detection and diagnosis of these diseases.
One of the potential applications of MIR23C as a biomarker is its ability to serve as a target for diagnostic agents, such as antibodies or diagnostic probes, that can detect and monitor the expression of MIR23C in various tissues and cells. This may have implications for the early detection and diagnosis of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In addition to its potential as a diagnostic biomarker, MIR23C may also have implications as a therapeutic target. The unique structure and function of MIR23C have led to the development of new therapeutic strategies, including small molecules, antibodies, and other therapeutic agents that can modulate the activity of MIR23C. These therapeutic agents may have implications for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
MIR23C as a Drug Target
MIR23C's unique structure and function have made it an attractive target for the development of new drugs, including small molecules, antibodies, and other therapeutic agents. The potential drug target that MIR23C may serve is the regulation of cellular signaling pathways, including the regulation of cell proliferation, apoptosis, and neurodegenerative diseases.
One of the most promising strategies for the development of drugs that target MIR23C is the use of small molecules that can modulate the activity of MIR23C. Small molecules that can interact with MIR23C's unique cysteine residue, as well as its unique arrangement of 11尾-helices, may have
Protein Name: MicroRNA 23c
The "MIR23C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR23C comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2
